American Cancer Society. Cancer facts & figures 2017 2017. https://www.cancer.org/research/cancer-facts-statistics/all-cancer-facts-figures/cancer-facts-figures-2017.html. Accessed 26 July 2017.
Howlader N, Noone AM, Krapcho M, Miller D BK, Kosary CL, Yu M, et al. SEER Cancer statistics review, 1975-2014 Bethesda, MD: National Cancer Institute; 2017 based on November 2016 SEER data submission. https://seer.cancer.gov/csr/1975_2014/. Accessed 3 July 2017.
Pritchard KI, Gelmon KA, Rayson D, Provencher L, Webster M, McLeod D, et al. Endocrine therapy for postmenopausal women with hormone receptor-positive her2-negative advanced breast cancer after progression or recurrence on nonsteroidal aromatase inhibitor therapy: a Canadian consensus statement. Curr Oncol. 2013;20(1):48–61.
Lewis S, Willis K, Yee J, Kilbreath S. Living well? strategies used by women LIVING with metastatic breast cancer. Qual Health Res. 2016;26(9):1167–79.
NIH—National Cancer Institute. Metastatic cancer. https://www.cancer.gov/types/metastatic-cancer.
Robertson JFR, Bondarenko IM, Trishkina E, Dvorkin M, Panasci L, Manikhas A, et al. Fulvestrant 500 mg versus anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON): an international, randomised, double-blind, phase 3 trial. Lancet. 2016;388(10063):2997–3005.
National Comprehensive Cancer Network (NCCN). Clinical practice guidelines in oncology—breast cancer version 3.2017 https://www.nccn.org/professionals/physician_gls/f_guidelines.asp. Accessed 8 Dec 2017.
NIH—National Cancer Institute. Hormone therapy for breast cancer https://www.cancer.gov/types/breast/breast-hormone-therapy-fact-sheet. Accessed 13 Sept 2017.
Bedard PL, Freedman OC, Howell A, Clemons M. Overcoming endocrine resistance in breast cancer: are signal transduction inhibitors the answer? Breast Cancer Res Treat. 2008;108(3):307–17.
Finn RS, Crown JP, Lang I, Boer K, Bondarenko IM, Kulyk SO, et al. The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study. Lancet Oncol. 2015;16(1):25–35.
Hortobagyi GN, Stemmer SM, Burris HA, Yap YS, Sonke GS, Paluch-Shimon S, et al. Ribociclib as first-line therapy for HR-positive, advanced breast cancer. N Engl J Med. 2016;375(18):1738–48.
Sledge GW Jr, Toi M, Neven P, Sohn J, Inoue K, Pivot X, et al. MONARCH 2: abemaciclib in combination with fulvestrant in women with HR+/HER2− advanced breast cancer who had progressed while receiving endocrine therapy. J Clin Oncol. 2017;35(25):2875–84.
Goetz MP, Toi M, Campone M, Sohn J, Paluch-Shimon S, Huober J, et al. MONARCH 3: abemaciclib as initial therapy for advanced breast cancer. J Clin Oncol. 2017;35(32):3638–46.
US Food and Drug Administration. IBRANCE® (palbociclib)—highlights of prescribing information https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/207103s000lbl.pdf. Accessed 13 Sept 2017.
US Food and Drug Administration. KISQALI® (ribociclib)—highlights of prescribing information https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/209092s000lbl.pdf. Accessed 17 Nov 2017.
US Food and Drug Administration. VERZENIO™ (abemaciclib)—Highlights of Prescribing Information https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208716s000lbl.pdf. Accessed 17 Nov 2017.
Accordino MK, Wright JD, Vasan S, Neugut AI, Hillyer GC, Hu JC, et al. Use and costs of disease monitoring in women with metastatic breast cancer. J Clin Oncol. 2016;34(24):2820–6.
Spring LM, Zangardi ML, Moy B, Bardia A. Clinical Management of Potential Toxicities and Drug Interactions Related to Cyclin-Dependent Kinase 4/6 Inhibitors in Breast Cancer: Practical Considerations and Recommendations. Oncologist. 2017;22:1039–48.
Kassem L, Shohdy KS, Lasheen S, Abdel-Rahman O, Bachelot T. Hematological adverse effects in breast cancer patients treated with cyclin-dependent kinase 4 and 6 inhibitors: a systematic review and meta-analysis. Breast Cancer. 2017;25:17–27.
Dalal AA, Gagnon-Sanschagrin P, Burne R, Guerin A, Gauthier G, Small T, et al. Dosing Patterns and Economic Burden of Palbociclib Drug Wastage in HR+/HER2- Metastatic Breast Cancer. Adv Ther. 2018. https://doi.org/10.1007/s12325-018-0701-5.
Quan H, Sundararajan V, Halfon P, Fong A, Burnand B, Luthi JC, et al. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care. 2005;43(11):1130–9.
Goldrick A, Olivotto IA, Alexander CS, Speers CH, Barnett J, Allan SJ, et al. Anemia is a common but neglected complication of adjuvant chemotherapy for early breast cancer. Curr Oncol. 2007;14(6):227–33.
Mouridsen H, Gershanovich M, Sun Y, Perez-Carrion R, Boni C, Monnier A, et al. Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: analysis of survival and update of efficacy from the International Letrozole Breast Cancer Group. J Clin Oncol. 2003;21(11):2101–9.
Nabholtz JM, Buzdar A, Pollak M, Harwin W, Burton G, Mangalik A, et al. Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. Arimidex Study Group. J Clin Oncol. 2000;18(22):3758–67.
Zhang Q, Shao Z, Shen K, Li L, Feng J, Tong Z, et al. Fulvestrant 500 mg vs 250 mg in postmenopausal women with estrogen receptor-positive advanced breast cancer: a randomized, double-blind registrational trial in China. Oncotarget. 2016;7(35):57301–9.